Jubilant Pharmova has been granted a patent for a stable radiopharmaceutical composition of tetrofosmin, providing high radiochemical purity and stability. The composition includes specific components and ratios, ensuring quality and effectiveness in diagnostic imaging procedures. GlobalData’s report on Jubilant Pharmova gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Data Insights Jubilant Pharmova Ltd - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Jubilant Pharmova, Graphene oxide composites was a key innovation area identified from patents. Jubilant Pharmova's grant share as of February 2024 was 37%. Grant share is based on the ratio of number of grants to total number of patents.

A recently granted patent (Publication Number: US11857647B2) discloses a reconstituted radiopharmaceutical composition that includes a first component comprising an aqueous solution of 99mTc pertechnetate and a second component with specific ingredients such as tetrofosmin disulfosalicylate, gentisic acid, a reducing agent, a transchelator, and sodium bicarbonate. The composition, free of ascorbate and antimicrobial preservatives, must have a radiochemical purity of at least 90% after 12 hours of storage at a temperature of 2-30°C. The molar ratio of tetrofosmin disulfosalicylate to gentisic acid, as well as the storage conditions for maintaining radiochemical purity, are also detailed in the claims.

Furthermore, the patent outlines a detailed process for preparing the reconstituted radiopharmaceutical composition, involving specific steps like lyophilization and mixing with the aqueous solution of 99mTc pertechnetate. The composition's components, their respective percentages, and the ratios between them are crucial for ensuring the desired radiochemical purity and stability. The patent also covers variations in the composition's ingredients and their proportions, emphasizing the importance of maintaining specific ratios for optimal performance. Overall, the patent provides a comprehensive guide for creating a liquid radiopharmaceutical composition with high radiochemical purity and stability under specified storage conditions.

To know more about GlobalData’s detailed insights on Jubilant Pharmova, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies